To better understand the effect of combined BRAFi and MEKi on resistance-associated mTORC1 signaling, we treated a panel of paired parental and CR BRAF mutant melanoma cell lines with PLX-4720 (PLX, 2.5 μM, BRAFi) and PD0325901 (PD, 0.25 μM, MEKi) for 24 h (Fig. 1). This evidence concerns the gene BRAF and melanoma.